PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers

By sjmartinez • November 14, 2024

Gu Y, Ly A, Rodriguez S, Zhang H, Kim J, Mao Z, Sachdeva A, Zomorodian N, Pellegrini M, Li G, Liu S, Drakaki A, Rettig MB, Chin AI. PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers. Cell Rep Med. 2024 Nov 6:101824. doi: 10.1016/j.xcrm.2024.101824. Epub ahead of print. PMID: 39536751.

Tags: Clinical Trial, Dermatology, Hematology/Oncology, immunochemotherapy, neuroendocrine prostate cancer, PD-1 blockade, Publications, single-cell sequencing, small cell bladder cancer, small cell cancers, T cell receptor sequencing, Veterans Administration

ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype

Assan F, Tragin M, Marella S, Lipecka J, Roger K, Zarhrate M, Bondet V, Nguyen V, Akroun F, Nitschké P, Guerrera IC, Bole C, Izmiryan[...]

A practical inflammatory blood-cell marker for cardiovascular risk stratification in psoriasis: Development of the Platelet-Leukocyte Adjusted Cardiovascular (PLAC) score

Cortes JA, Aflatooni S, Ure A, Palma G, Johnsen N, Smart K, Nong Y, Armstrong AW. A practical inflammatory blood-cell marker for cardiovascular risk stratification[...]

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials

Stein Gold L, Armstrong AW, Soung J, Vender RB, González Cantero Á, Hoffmann M, Guenthner ST, Hong HC, Murrell DF, Song EJ, Kircik L, Augustin[...]